Compare Harley-Davidson Inc (HOG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Moderna, Inc. — how do they compare? Harley-Davidson Inc trades at $25.99 (market cap $2.78B), while Moderna, Inc. trades at $64.15 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 8.7× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| HOG | MRNA | |
|---|---|---|
Market Cap | $2.78B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $81.80 |
52-Week Low | $17.19 | $22.36 |
Enterprise Value | $3.19B | $20.33B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $25.95, down 0.57% with a bullish technical signal. The company reported Q2 2026 EPS of $0.75 beating estimates of $0.645, though revenue declined to $4.47B in 2025 from $5.8B in 2022. Valuation metrics appear reasonable with P/E of 14.84 and P/S of 0.72. Recent news highlights production returning to US facilities and raised 2026 guidance following stronger North American sales.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include cost-cutting initiatives and domestic production advantages, while risks involve ongoing revenue pressure, competitive threats from Indian Motorcycle, and margin compression from rising raw material costs evident in recent quarterly results.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
